10-Q: Charlie's Holdings Reports Q1 Revenue Decline Amid Strategic Shift, Bolstered by Post-Period Asset Sale to R.J. Reynolds

Charlie's Holdings, a producer of nicotine and alternative vapor products, reported a 24.4% revenue decrease and increased net loss for Q1 2025, but significantly improved its financial position through a $6.5 million asset sale to R.J. Reynolds Vapor Company post-period, addressing going concern doubts.

Summary

• For the three months ended March 31, 2025, Charlie's Holdings reported total revenues of $2.306 million, a decrease of 24.4% from $3.051 million in the same period of 2024.
• The company incurred a net loss of $1.217 million for Q1 2025, an increase from a net loss of $1.045 million in Q1 2024.
• Loss from operations improved slightly to $0.826 million in Q1 2025, compared to $0.941 million in Q1 2024.
• Cash used in operating activities was $0.409 million for Q1 2025, a slight improvement from $0.431 million in Q1 2024.
• As of March 31, 2025, the company had a working capital deficit of $2.829 million, an increase from $1.855 million at December 31, 2024.
• Post-period, on April 16, 2025, and May 29, 2025, the company sold 15 PACHA synthetic products and related assets to R.J. Reynolds Vapor Company for a combined purchase price of $6.5 million, plus a contingent one-time payment of up to $4.2 million.
• These asset sales have substantially addressed the company's debt and working capital short-term concerns and improved its cash position, mitigating previous substantial doubt about its ability to continue as a going concern.
• The company has implemented cost-cutting measures, including salary reductions of up to 50% for officers and certain managers, and a reduction in headcount.
• Charlie's launched SBX, a non-nicotine, disposable vapor product, in Q4 2024, which the company believes is not subject to FDA review.
• The company has invested over $6.5 million in its Premarket Tobacco Application (PMTA) process for FDA submissions and holds over 650 FDA Acceptance Filings for PMTAs.

Sentiment

Score: 6

Explanation: While Q1 financial results were poor (revenue decline, increased net loss, increased working capital deficit), the significant asset sale to R.J. Reynolds Vapor Company post-period, totaling $6.5 million upfront with potential for $4.2 million more, substantially addresses immediate liquidity and going concern issues. This positive subsequent event, coupled with strategic initiatives in non-nicotine products and PMTA monetization, shifts the sentiment from highly negative to cautiously optimistic, as the company has secured a lifeline and a clearer path forward, despite ongoing operational challenges.

Positives

• The company successfully executed an Asset Purchase Agreement with R.J. Reynolds Vapor Company, selling 15 PACHA synthetic products and related assets for $6.5 million upfront, with a potential additional $4.2 million contingent payment, significantly improving liquidity.
• The asset sales have 'substantially addressed' debt and working capital short-term concerns, and 'improved' the company's cash position, mitigating the going concern risk.
• Cash used in operating activities decreased to $409,000 in Q1 2025 from $431,000 in Q1 2024, indicating a slight improvement in operational cash burn.
• Loss from operations decreased to $826,000 in Q1 2025 from $941,000 in Q1 2024, showing an improvement in core operational efficiency.
• The launch of the SBX non-nicotine, disposable vapor product in Q4 2024 provides a strategic hedge against FDA regulations, as the company believes it is not subject to FDA review.
• The company has invested over $6.5 million in PMTA submissions and holds over 650 FDA Acceptance Filings, which are considered a significant competitive advantage and asset for potential monetization.
• Cost-cutting measures, including executive salary reductions (20-50%) and headcount reductions, demonstrate management's commitment to right-sizing the business and improving margins.
• The company secured a discount of approximately $99,000 by satisfying the Pinnacle Receivables Financing Agreement in full prior to April 16, 2025.

Negatives

• Total revenues for Q1 2025 decreased by 24.4% to $2.306 million from $3.051 million in Q1 2024, primarily due to a $1.296 million decrease in sales of nicotine-based vapor products.
• The company's net loss increased to $1.217 million in Q1 2025 from $1.045 million in Q1 2024.
• The working capital deficit increased to $2.829 million at March 31, 2025, from $1.855 million at December 31, 2024.
• Cost of goods sold as a percentage of revenue increased to 77.1% in Q1 2025 from 69.1% in Q1 2024, indicating lower fixed cost absorption and overall margin compression.
• Interest expense increased by 32.2% to $242,000 in Q1 2025, primarily due to an increase in outstanding notes payable.
• The company recognized a debt extinguishment loss of $149,000 in Q1 2025 related to the restructuring of the Pinnacle Receivables Financing Agreement and settlement of the Chemular Note.
• The launch of the SPREE BAR nicotine substitute vapor products did not meet performance expectations, requiring further development efforts.

Risks

• The company operates in a rapidly changing legal and regulatory environment, with new laws or changes to existing laws potentially limiting product sales or increasing costs.
• Substantial doubt exists about the company's ability to continue as a going concern due to declining revenue, operating losses, net losses, low working capital, and cash position, despite recent asset sales.
• The company is required to obtain FDA approval for its nicotine vaporization products, and there is no assurance that previous or future applications will be approved, potentially leading to Marketing Denial Orders (MDOs).
• MDOs from the FDA could result in inventory obsolescence, uncollectable accounts receivables, and the requirement to remove products from circulation.
• Certain states and municipalities have banned or are considering banning flavored e-cigarettes, which directly limits the markets where the company can sell its products.
• The FDA has asserted authority over synthetic nicotine, requiring PMTAs for the company's Pacha brands; the FDA may bring enforcement actions or issue MDOs at any time.
• The company's belief that its Metatine-based SBX products are not subject to FDA review could be incorrect, or Congress/FDA could assert jurisdiction, potentially requiring premarket authorization and leading to enforcement actions.
• The company may require additional financing in the future for new product categories or subsequent PMTA filings, and there is no assurance such financing will be available on acceptable terms or at all.
• If the company does not have sufficient funds to continue operations, it could be required to seek bankruptcy protection or other alternatives, potentially leading to stockholders losing their investment.
• The company's ability to utilize its net operating losses (NOLs) and tax credit carryforwards may be limited by ownership changes or regulatory changes.

Future Outlook

The company's future plans and growth depend on its ability to increase revenues, procure cost-effective financing, and continue business development efforts. Management believes its strategic initiatives, including the SBX product line and monetization of PMTA assets, will enhance its competitive position, reduce costs, accelerate profitability, support growth, and enable an uplist to a national securities exchange. The company is also developing Metatine-based e-liquids and pouches for late 2025 market readiness. While the recent asset sales have addressed short-term liquidity concerns, additional financing may be required for new product categories or future PMTA filings.

Management Comments

• "Our plans and growth depend on our ability to increase revenues, procure cost-effective financing, and continue our business development efforts."
• "The Company believes Charlies 650+ PMTAs, as a stand-alone asset, have a monetary value that far exceeds Charlies current market cap."
• "Management believes that these initiatives will enhance Charlies competitive position in the marketplace, significantly reduce costs, help accelerate the Companys path to profitability, support business growth, and, ultimately, allow the Company to achieve greater liquidity and visibility through an uplist to a national securities exchange."
• "We believe adult consumers will enjoy Metatine alternative alkaloid vapor products in much the same way that they enjoy traditional vapor products."
• "Notably, because Metatine is not made or derived from tobacco, and because Metatine does not consist of or contain nicotine from any source, the FDA's Center for Tobacco Products does not have jurisdiction to regulate Metatine."
• "In a Company-sponsored focus group survey of adult consumers who vape, Charlie's SBX Disposables were overwhelming preferred over Juul tobacco-flavored vapes. Of 306 survey participants, 287 preferred SBX over Juul."
• "Compared to mass-market vapes offered by Big Tobacco namely Juul SBX provides many MORE FLAVOR options, UNBEATABLE TAX ADVANTAGES, and THOUSANDS MORE PUFFS!"
• "We believe that our substantial investments in FDA regulatory compliance make Charlies an attractive partner in this space."
• "Obtaining one or more marketing orders from the FDA could, we believe, help to remediate perceived health issues related to vaping, and further position the Company as a trusted industry leader."
• "We believe age-gating is both a responsible business practice as well as a potential future competitive advantage for Charlies."
• "Presently, approximately 10% of our vapor product sales come from the international market and we are well positioned to increase sales in countries where we already have presence and, in additional overseas markets, as we have already built an international distribution platform."

Industry Context

The vapor products industry is characterized by rapid regulatory changes, with increasing scrutiny from the FDA and state/local governments regarding flavored e-cigarettes and synthetic nicotine. The FDA's stringent PMTA process has resulted in very few approvals, creating a challenging environment for many companies. Charlie's strategic shift towards non-nicotine products like SBX (Metatine-based) and its focus on age-gating technology are direct responses to these regulatory pressures and evolving consumer preferences for flavored alternatives. The asset sale to R.J. Reynolds Vapor Company highlights the consolidation and strategic partnerships occurring within the industry as larger players seek to acquire PMTA-covered assets.

Comparison to Industry Standards

• The company's investment of over $6.5 million in PMTA submissions and its 650+ FDA Acceptance Filings for PMTAs are substantial, especially considering that the FDA has authorized fewer than 1% of the over 26 million PMTAs submitted across the industry.
• The company's development of age-gating technology aligns with initiatives by major industry players like JUUL Labs, Altria, and R.J. Reynolds, who are also investing in technologies to prevent underage access, indicating a shared industry focus on regulatory compliance and responsible business practices.
• The reported preference of SBX over Juul tobacco-flavored vapes in a company-sponsored survey (287 out of 306 participants) suggests a strong consumer appetite for flavored, non-nicotine alternatives, potentially positioning SBX favorably against traditional tobacco-focused products in the market.
• The company's claim of 'UNBEATABLE TAX ADVANTAGES' for SBX compared to mass-market vapes like Juul suggests a competitive edge in a highly taxed industry, which could attract regional and national convenience store chains.

Management Changes

Corporate Governance

Legal Proceedings

• As of the filing date, the company is not a party to any material legal or administrative proceedings.
• There are no proceedings in which any directors, executive officers, affiliates, or stockholders are adverse parties or have a material interest adverse to the company's interest.
• The company may be involved in various claims and counterclaims and legal actions arising in the ordinary course of business, which could result in substantial cost and diversion of resources.

Related Party Transactions

• Don Polly, LLC, a consolidated variable interest entity, is owned by entities controlled by Ryan Stump, a current executive officer. The company is the primary beneficiary and receives 100% of net income or incurs 100% of net loss.
• A two-month short-term loan agreement for $100,000 was entered into on February 27, 2025, with Henry Sicignano III, the company's President.
• Unsecured promissory notes totaling $1,400,000 (July 2023 Notes) were issued to several executives (Ryan Stump, Henry Sicignano III, Keith Stump, Jessica Greenwald) and largest stockholders (Brandon Stump, Red Beard Holdings LLC, Michael King). As of March 31, 2025, $400,000 remained outstanding with Ryan Stump and Henry Sicignano III, with maturity extended to April 1, 2025, and further modified on April 28, 2025.
• A secured promissory note for $1,000,000 (April 2022 Note) was issued to Michael King, a large individual stockholder and Board member. Approximately $781,000 remained outstanding as of March 31, 2025, and was modified on April 28, 2025.
• A loan agreement for $300,000 (August 2022 Loan) was entered into with Ryan Stump, the Chief Operating Officer and Director, and was fully satisfied on April 28, 2025.
• The company leases its corporate headquarters in Costa Mesa, California, from Brandon Stump (former CEO), Ryan Stump (COO), and Keith Stump (former Board member). Total rent paid to related parties for this lease was approximately $69,000 for the three months ended March 31, 2025 and 2024.
• The company leases sales and marketing operations space in Williamsville, New York, from Henry Sicignano Jr., a relative of the company's President, Henry Sicignano III. The lease was extended on May 1, 2024.

Stakeholder Impact

• **Shareholders**: The asset sale to R.J. Reynolds Vapor Company significantly reduces immediate financial risk and addresses going concern doubts, potentially stabilizing or improving share price. However, Q1 operational results show continued revenue decline and net losses, which could be a concern for long-term profitability without new growth drivers. Dilution risk from potential future capital raises remains.
• **Employees**: Cost-cutting measures, including salary reductions (up to 50% for officers and managers) and headcount reductions, indicate a challenging environment for employees, though these measures are aimed at ensuring the company's survival.
• **Customers**: The company's focus on new non-nicotine products (SBX) and continued efforts to secure FDA authorization for existing products aim to provide a broader and more compliant product offering, potentially benefiting customers seeking alternatives.
• **Suppliers/Creditors**: The substantial debt repayments and modifications post-period, facilitated by the asset sale, improve the company's ability to meet its obligations, reducing risk for creditors and potentially strengthening supplier relationships.
• **Regulatory Authorities**: The company's significant investment in PMTA submissions and development of age-gating technology demonstrates a commitment to regulatory compliance, which may be viewed favorably by the FDA, though regulatory risks remain high.

Next Steps

• Increase revenues and procure cost-effective financing.
• Continue business development efforts, including supporting the PMTA process.
• Further develop and test market the SBX Metatine-based disposable vapor products in mass market convenience chains.
• Develop Metatine-based e-liquids under the PACHAMAMA PLUS+ trademark.
• Develop a Metatine-based pouch line, aiming for market readiness in late 2025.
• Seek strategic partners to monetize the company's 650+ PMTAs.
• Continue developing intellectual property around and seeking strategic partnerships for age-gating technologies.
• Increase market share internationally, leveraging existing distribution platforms.
• Uplist from the OTCQB exchange to a national securities exchange as business returns to growth and listing requirements are met.
• Work with the landlord to renew the lease for the Huntington Beach, CA facility, currently on a month-to-month basis.

Key Dates

Recommendation

Keywords

Vapor products, Nicotine, Synthetic nicotine, FDA regulation, PMTA, Premarket Tobacco Application, SBX, Metatine, E-cigarettes, Disposable vapes, Age-gating technology, Financial reporting, SEC filing, Going concern, Asset sale, R.J. Reynolds, Debt reduction, Cost optimization, OTC Markets